Bitopertin is under clinical development by Disc Medicine and currently in Phase II for Porphyria (Erythropoietic Protoporphyri). According to GlobalData, Phase II drugs for Porphyria (Erythropoietic Protoporphyri) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bitopertin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bitopertin overview

Bitopertin is under development for the treatment of erythropoietic porphyrias (EP) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) and diamond-blackfan anemia (DBA). The drug candidate is administered through oral route. It is a first-in-class glycine reuptake inhibitor (glycine transporter type 1).

It was under development for the treatment of beta thalassemia and sub-optimally controlled positive symptoms of schizophrenia and obsessive-compulsive disorder

Disc Medicine overview

Disc Medicine, formerly Gemini Therapeutics Inc, is a biotechnology company, which develops first-in-class, disease-modifying precision medicines for dry age-related macular degeneration (AMD) and associated rare genetic diseases. The company product pipeline includes GEM103, a recombinant form of the human complement factor H protein that is designed to address complement hyperactivity and overall dysregulation and GEM307 to target complement factor H. The company works in partnership with research institutions and innovative companies including StrideBio Inc, Sanquin, Newcastle University, and The University of Edinburgh for precision therapeutic and development strategies. Disc Medicine is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Bitopertin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.